<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930943</url>
  </required_header>
  <id_info>
    <org_study_id>2009-133A</org_study_id>
    <nct_id>NCT00930943</nct_id>
  </id_info>
  <brief_title>Effect of Extended-release Oxymorphone Taking With or Without Food on Cognitive Functioning</brief_title>
  <official_title>Effect of Extended-release Oxymorphone Hydrochloride (Opana® ER), Taken Fasting Versus With Food, on Cognitive Functioning in Opioid-tolerant Subjects: a Randomized, Single-blinded, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedVadis Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedVadis Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether extended-release oxymorphone hydrochloride&#xD;
      taken orally with a high-fat meal, generating an approximately 50% higher Cmax, impacts&#xD;
      cognitive functioning, using Cambridge Neuropsychological Test Automated Battery (CANTAB)&#xD;
      tests, to a greater extent than when taking under conditions of fasting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rapid Visual Information Processing Test</measure>
    <time_frame>1 and 3 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spatial Recognition Memory test</measure>
    <time_frame>1 and 3 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spatial Working Memory Test</measure>
    <time_frame>1 and 3 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Recognition Memory Test</measure>
    <time_frame>1 and 3 hours postdose</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymorphone ER (Opana ER)</intervention_name>
    <description>40 mg qd twice</description>
    <other_name>Opana ER</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Man or woman, 18-65 years of age, inclusive&#xD;
&#xD;
          2. Able to provide informed consent and comply with all study procedures&#xD;
&#xD;
          3. Women of childbearing potential with a negative urine pregnancy test at screening and&#xD;
             on adequate contraception&#xD;
&#xD;
          4. Chronic, non-malignant, painful condition, treated with long-acting opioid (methadone,&#xD;
             OxyContin®, MS Contin®, Kadian®, Avinza®, Fentanyl®, Opana® ER)&#xD;
&#xD;
          5. Opioid treatment for at least 3 months prior to screening at a minimum dose of 90 mg&#xD;
             of morphine equivalents per day or 50 mcg of the fentanyl transdermal patch&#xD;
&#xD;
          6. Dose of opioid treatment stable for at least 1 week prior to screening and expected to&#xD;
             be stable from screening through end of second testing&#xD;
&#xD;
          7. Weight at screening 100-300 pounds, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding&#xD;
&#xD;
          2. Gastrointestinal disorder or S/P gastrointestinal surgery impacting absorption of&#xD;
             study medication (delayed gastric emptying, partial or complete gastrectomy)&#xD;
&#xD;
          3. Alcohol or substance abuse within 2 years of screening&#xD;
&#xD;
          4. Consumption of alcohol within 24 hours of a screening or testing visit&#xD;
&#xD;
          5. Consumption of xanthine-containing beverages (coffee, tea, coke) on the morning of a&#xD;
             screening or testing visit&#xD;
&#xD;
          6. Impaired kidney or liver function (transaminase levels more than 3 times elevated;&#xD;
             estimated creatinine clearance less than 50 mL/min)&#xD;
&#xD;
          7. Epworth sleepiness scale (ESS) score 16 or higher at screening&#xD;
&#xD;
          8. Medically concerning hypertension (≥ 160/100) or unstable cardiovascular illness&#xD;
&#xD;
          9. Any clinically significant illness that would interfere with study participation or&#xD;
             put the subject at risk&#xD;
&#xD;
         10. Exposure to investigational medication within 30 days of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egilius LH Spierings, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedVadis Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedVadis Research Corporation</name>
      <address>
        <city>Wellesley Hills</city>
        <state>Massachusetts</state>
        <zip>02481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>September 8, 2011</last_update_submitted>
  <last_update_submitted_qc>September 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid tolerant</keyword>
  <keyword>chronic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymorphone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 19, 2012</submitted>
    <returned>May 17, 2012</returned>
    <submitted>May 17, 2012</submitted>
    <returned>June 19, 2012</returned>
    <submitted>August 30, 2017</submitted>
    <returned>September 26, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

